{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:38:45Z","timestamp":1792042725458,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1187628"],"award-info":[{"award-number":["OPP1187628"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While Seasonal Malaria Chemoprevention (SMC) has been adopted as a malaria control strategy in regions with seasonal transmission, continued monitoring and evaluation of its effectiveness across diverse ecological, epidemiological, and healthcare settings remain critical for optimizing the intervention. This study aims to assess the ongoing population-level impact of SMC under routine programme conditions by evaluating rates of uncomplicated and severe malaria following four rounds of administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A pre-post analysis was conducted using real-world surveillance data from clinic visits in 285 villages in Nouna District, Burkina Faso, along with National Malaria Control Programme data on SMC administration. Estimates of the population used for person-time calculations were derived from a census conducted as part of a randomized controlled trial. Malaria rates for children under 5 were analyzed for each epidemiological week in 2021, for each health post in the study area. Negative binomial regression models were used, with person-time at risk used as an offset and standard errors clustered by health post, to obtain incidence rate ratios (IRRs) and rate differences. Changes in diagnoses were estimated from the administration weeks to each of the three weeks post- administration within the same population. Injury rates were used as a negative control outcome to assess potential unmeasured confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Although SMC was administered during peak malaria transmission weeks within each cycle, both uncomplicated and severe malaria rates remained high through December, following the fourth and final round of SMC. There was a substantial reduction in infection rates in the 3\u00a0weeks post SMC, with gradual increases in rates across the three weeks. The rates of uncomplicated and severe malaria per 1000 person-weeks in the administration weeks were 8.5 (95% CI 7.0 to 10.1) and 0.31 (95% CI 0.22 to 0.40), respectively. Uncomplicated malaria rates were lower by 41%, 95%CI (31\u201350%), 34% (23\u201343%) and 22% (12\u201331%) in the first, second and third weeks after administration, respectively. Severe malaria rates declined by 47% (21\u201364%), 47% (31\u201359%) and 34% (17\u201347%) in the three weeks post-administration. Injury rates, the negative control outcome, did not change significantly across the three weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In programme settings, at the population level, SMC administration was associated with a substantial reduction in uncomplicated and severe malaria, though this effect was limited to the immediate weeks following administration. The gradual increase in malaria rates by the third week suggests a shorter duration of protection than previously observed. Extending the areas where 5 rounds of distribution occur may be necessary to effectively prevent malaria infections in regions with a longer transmission season. Regular evaluation of local malaria trends and impact of SMC can help further tailor and optimize SMC programmes for specific regional contexts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-025-05597-y","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T07:48:50Z","timestamp":1762415330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Trends in uncomplicated and severe malaria following seasonal malaria chemoprevention administration in Nouna, Burkina Faso: a quasi-experimental pre-post study"],"prefix":"10.1186","volume":"24","author":[{"given":"Elisabeth A.","family":"Gebreegziabher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou","family":"Ouattara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou","family":"Bountogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boubacar","family":"Coulibaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Boudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Ouedraogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Lebas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David V.","family":"Glidden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin F.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Lietman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Si\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine E.","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"5597_CR1","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/S2214-109X(21)00515-5","volume":"10","author":"D Sharrow","year":"2022","unstructured":"Sharrow D, Hug L, You D, Alkema L, Black R, Cousens S, et al. Global, regional, and national trends in under-5 mortality between 1990 and 2019 with scenario-based projections until 2030: a systematic analysis by the UN inter-agency group for child mortality estimation. Lancet Glob Health. 2022;10:e195\u2013206.","journal-title":"Lancet Glob Health"},{"key":"5597_CR2","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/S0140-6736(17)31758-0","volume":"390","author":"N Golding","year":"2017","unstructured":"Golding N, Burstein R, Longbottom J, Browne AJ, Fullman N, Osgood-Zimmerman A, et al. Mapping under-5 and neonatal mortality in Africa, 2000\u201315: a baseline analysis for the sustainable development goals. Lancet. 2017;390:2171\u201382.","journal-title":"Lancet"},{"key":"5597_CR3","first-page":"Cd012882","volume":"2","author":"NP Oliphant","year":"2021","unstructured":"Oliphant NP, Manda S, Daniels K, Odendaal WA, Besada D, Kinney M, et al. Integrated community case management of childhood illness in low- and middle-income countries. Cochrane Database Syst Rev. 2021;2:Cd012882.","journal-title":"Cochrane Database Syst Rev"},{"key":"5597_CR4","first-page":"127","volume-title":"Malaria prevention works, let\u2019s close the gap","author":"WHO","year":"2017","unstructured":"WHO. Malaria prevention works, let\u2019s close the gap. Geneva: World Health Organization; 2017. p. 127\u20139."},{"key":"5597_CR5","unstructured":"WHO. Seasonal malaria chemoprevention with sulfadoxine\u2013pyrimethamine plus amodiaquine in children: a field guide. Global Malaria Programme. 2nd Edn. Geneva: World Health Organization. 2023."},{"key":"5597_CR6","unstructured":"SMC Alliance. 53 million children living in 18 countries covered with Seasonal Malaria Chemoprevention in 2023. Accessed 4 Mar 2025, 5 Apr 2024."},{"key":"5597_CR7","volume-title":"Guidelines for malaria","author":"WHO","year":"2023","unstructured":"WHO. Guidelines for malaria. Geneva: World Health Organization; 2023."},{"key":"5597_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-03175-y","volume":"19","author":"D Issiaka","year":"2020","unstructured":"Issiaka D, Barry A, Traore T, Diarra B, Cook D, Keita M, et al. Impact of seasonal malaria chemoprevention on hospital admissions and mortality in children under 5 years of age in Ouelessebougou, Mali. Malar J. 2020;19:103.","journal-title":"Malar J"},{"key":"5597_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000407","volume":"8","author":"A Dicko","year":"2011","unstructured":"Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, et al. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011;8:e1000407.","journal-title":"PLoS Med"},{"key":"5597_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-024-04853-x","volume":"23","author":"J Khan","year":"2024","unstructured":"Khan J, Suau Sans M, Okot F, Rom Ayuiel A, Magoola J, Rassi C, et al. A quasi-experimental study to estimate effectiveness of seasonal malaria chemoprevention in Aweil South County in Northern Bahr El Ghazal, South Sudan. Malar J. 2024;23:33.","journal-title":"Malar J"},{"key":"5597_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290233","volume":"18","author":"C Bationo","year":"2023","unstructured":"Bationo C, Cissoko M, Katil\u00e9 A, Sylla B, Ou\u00e9draogo A, Ouedraogo JB, et al. Malaria in Burkina Faso: a comprehensive analysis of spatiotemporal distribution of incidence and environmental drivers, and implications for control strategies. PLoS ONE. 2023;18:e0290233.","journal-title":"PLoS ONE"},{"key":"5597_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003214","volume":"17","author":"ME Cairns","year":"2020","unstructured":"Cairns ME, Sagara I, Zongo I, Kuepfer I, Thera I, Nikiema F, et al. Evaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: secondary analysis of a household-randomised, placebo-controlled trial in Hound\u00e9 district, Burkina Faso and Bougouni district, Mali. PLoS Med. 2020;17:e1003214.","journal-title":"PLoS Med"},{"key":"5597_CR13","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(20)32227-3","volume":"396","author":"Partnership A-S","year":"2020","unstructured":"Partnership A-S. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet. 2020;396:1829\u201340.","journal-title":"Lancet"},{"key":"5597_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jama.2023.27393","volume":"331","author":"CE Oldenburg","year":"2024","unstructured":"Oldenburg CE, Ouattara M, Bountogo M, Boudo V, Ouedraogo T, Compaor\u00e9 G, et al. Mass azithromycin distribution to prevent child mortality in Burkina Faso: the CHAT randomized clinical trial. JAMA. 2024;331:482\u201390.","journal-title":"JAMA"},{"key":"5597_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1186\/s13063-019-3855-9","volume":"20","author":"A Si\u00e9","year":"2019","unstructured":"Si\u00e9 A, Ouattara M, Bountogo M, Bagagnan C, Coulibaly B, Boudo V, et al. A double-masked placebo-controlled trial of azithromycin to prevent child mortality in Burkina Faso, West Africa: community health with azithromycin trial (CHAT) study protocol. Trials. 2019;20:675.","journal-title":"Trials"},{"key":"5597_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12913-021-06226-5","volume":"21","author":"CE Oldenburg","year":"2021","unstructured":"Oldenburg CE, Si\u00e9 A, Ouattara M, Bountogo M, Boudo V, Kouanda I, et al. Distance to primary care facilities and healthcare utilization for preschool children in rural northwestern Burkina Faso: results from a surveillance cohort. BMC Health Serv Res. 2021;21:212.","journal-title":"BMC Health Serv Res"},{"key":"5597_CR17","volume-title":"a practical handbook","author":"Management of severe malaria","year":"2012","unstructured":"Management of severe malaria. a practical handbook. 3rd ed. Geneva: World Health Organization; 2012.","edition":"3"},{"key":"5597_CR18","unstructured":"Arias JR. EPI Week Calendars 2008\u20132024. Central MassMosquito Control Project. 585"},{"key":"5597_CR19","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/infdis\/jiad172","volume":"228","author":"ME Roh","year":"2023","unstructured":"Roh ME, Zongo I, Haro A, Huang L, Som\u00e9 AF, Yerbanga RS, et al. Seasonal malaria chemoprevention drug levels and drug resistance markers in children with or without malaria in Burkina Faso: a case-control study. J Infect Dis. 2023;228:926\u201335.","journal-title":"J Infect Dis"},{"key":"5597_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1017\/S1049023X19005053","volume":"34","author":"SJ Stratton","year":"2019","unstructured":"Stratton SJ. Quasi-experimental design (pre-test and post-test studies) in prehospital and disaster research. Prehosp Disaster Med. 2019;34:573\u20134.","journal-title":"Prehosp Disaster Med"},{"key":"5597_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002227","volume":"3","author":"M Cairns","year":"2008","unstructured":"Cairns M, Carneiro I, Milligan P, Owusu-Agyei S, Awine T, Gosling R, et al. Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PLoS ONE. 2008;3:e2227.","journal-title":"PLoS ONE"},{"key":"5597_CR22","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1128\/AAC.04923-14","volume":"59","author":"I Zongo","year":"2015","unstructured":"Zongo I, Milligan P, Compaore YD, Some AF, Greenwood B, Tarning J, et al. Randomized noninferiority trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother. 2015;59:4387\u201396.","journal-title":"Antimicrob Agents Chemother"},{"key":"5597_CR23","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1093\/ije\/dyy135","volume":"47","author":"J Lopez Bernal","year":"2018","unstructured":"Lopez Bernal J, Cummins S, Gasparrini A. The use of controls in interrupted time series studies of public health interventions. Int J Epidemiol. 2018;47:2082\u201393.","journal-title":"Int J Epidemiol"},{"key":"5597_CR24","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1001\/jama.2016.17700","volume":"316","author":"BF Arnold","year":"2016","unstructured":"Arnold BF, Ercumen A. Negative control outcomes: a tool to detect bias in randomized trials. JAMA. 2016;316:2597\u20138.","journal-title":"JAMA"},{"key":"5597_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","volume":"21","author":"M Lipsitch","year":"2010","unstructured":"Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21:383\u20138.","journal-title":"Epidemiology"},{"key":"5597_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-12741-9","volume":"22","author":"A Traore","year":"2022","unstructured":"Traore A, Donovan L, Sawadogo B, Ward C, Smith H, Rassi C, et al. Extending seasonal malaria chemoprevention to five cycles: a pilot study of feasibility and acceptability in Mangodara district, Burkina Faso. BMC Public Health. 2022;22:442.","journal-title":"BMC Public Health"},{"key":"5597_CR27","unstructured":"Climate and Average Weather Year Round in Nouna, Burkina Faso. Weather Spark. 2016."},{"key":"5597_CR28","unstructured":"Sawadogo B, Matusse C, Sewu E, Lokang F, Khan J, Ibinaye T, Kyagulanyi T, Cook L, Compaore C, Giles A, Rassi C, Tibenderana J. Coverage and quality of seasonal malaria chemoprevention supported by Malaria Consortium in 2022: Results from Burkina Faso, Chad, Mozambique, Nigeria, South Sudan, Togo and Uganda. Malaria Consortium. 2023."},{"key":"5597_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-016-1251-4","volume":"15","author":"M Tour\u00e9","year":"2016","unstructured":"Tour\u00e9 M, Sanogo D, Dembele S, Diawara SI, Oppfeldt K, Schi\u00f8ler KL, et al. Seasonality and shift in age-specific malaria prevalence and incidence in Binko and Carri\u00e8re villages close to the lake in Selingu\u00e9, Mali. Malar J. 2016;15:219.","journal-title":"Malar J"},{"key":"5597_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/17441690903352572","volume":"5","author":"SE Findley","year":"2010","unstructured":"Findley SE, Medina DC, Sogoba N, Guindo B, Doumbia S. Seasonality of childhood infectious diseases in Niono, Mali. Glob Public Health. 2010;5:381\u201394.","journal-title":"Glob Public Health"},{"key":"5597_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12936-022-04068-y","volume":"21","author":"A Amare","year":"2022","unstructured":"Amare A, Eshetu T, Lemma W. Dry-season transmission and determinants of Plasmodium infections in Jawi district, northwest Ethiopia. Malar J. 2022;21:45.","journal-title":"Malar J"},{"key":"5597_CR32","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/s41591-020-1084-0","volume":"26","author":"CM Andrade","year":"2020","unstructured":"Andrade CM, Fleckenstein H, Thomson-Luque R, Doumbo S, Lima NF, Anderson C, et al. Increased circulation time of Plasmodium falciparum underlies persistent asymptomatic infection in the dry season. Nat Med. 2020;26:1929\u201340.","journal-title":"Nat Med"},{"key":"5597_CR33","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/tmi.12642","volume":"21","author":"H Tagbor","year":"2016","unstructured":"Tagbor H, Antwi GD, Acheampong PR, Bart Plange C, Chandramohan D, Cairns M. Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial. Trop Med Int Health. 2016;21:224\u201335.","journal-title":"Trop Med Int Health"},{"key":"5597_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.parepi.2022.e00283","volume":"20","author":"D Konate","year":"2023","unstructured":"Konate D, Diawara SI, Sogoba N, Shaffer J, Keita B, Cisse A, et al. Effect of a fifth round of seasonal malaria chemoprevention in children aged 5\u201314 years in Dangassa, an area of long transmission in Mali. Parasite Epidemiol Contr. 2023;20:e00283.","journal-title":"Parasite Epidemiol Contr"},{"key":"5597_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166951","volume":"11","author":"GD Antwi","year":"2016","unstructured":"Antwi GD, Bates LA, King R, Mahama PR, Tagbor H, Cairns M, et al. Facilitators and barriers to uptake of an extended seasonal malaria chemoprevention programme in Ghana: a qualitative study of caregivers and community health workers. PLoS ONE. 2016;11:e0166951.","journal-title":"PLoS ONE"},{"key":"5597_CR36","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12916-022-02536-5","volume":"20","author":"M Cairns","year":"2022","unstructured":"Cairns M, Barry A, Zongo I, Sagara I, Yerbanga SR, Diarra M, et al. The duration of protection against clinical malaria provided by the combination of seasonal RTS, s\/AS01(E) vaccination and seasonal malaria chemoprevention versus either intervention given alone. BMC Med. 2022;20:352.","journal-title":"BMC Med"},{"key":"5597_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12916-020-1494-3","volume":"18","author":"MT Bretscher","year":"2020","unstructured":"Bretscher MT, Dahal P, Griffin J, Stepniewska K, Bassat Q, Baudin E, et al. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Med. 2020;18:47.","journal-title":"BMC Med"},{"key":"5597_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012618","volume":"5","author":"JT Griffin","year":"2010","unstructured":"Griffin JT, Cairns M, Ghani AC, Roper C, Schellenberg D, Carneiro I, et al. Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS ONE. 2010;5:e12618.","journal-title":"PLoS ONE"},{"key":"5597_CR39","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12936-019-3057-7","volume":"18","author":"M van Lenthe","year":"2019","unstructured":"van Lenthe M, van der Meulen R, Lassovski M, Ouabo A, Bakula E, Badio C, et al. Markers of sulfadoxine-pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention. Malar J. 2019;18:430.","journal-title":"Malar J"},{"issue":"3","key":"5597_CR40","first-page":"478","volume":"12","author":"L Braunack-Mayer","year":"2023","unstructured":"Braunack-Mayer L, Malinga J, Masserey T, Nekkab N, Sen S, Schellenberg D, et al. Design and selection of drug properties to increase the public health impact of next-generation seasonal malaria chemoprevention: a modelling study. medRxiv. 2023;12(3):478\u201390.","journal-title":"medRxiv"},{"key":"5597_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12936-022-04059-z","volume":"21","author":"A Mahamar","year":"2022","unstructured":"Mahamar A, Sumner KM, Levitt B, Freedman B, Traore A, Barry A, et al. Effect of three years\u2019 seasonal malaria chemoprevention on molecular markers of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou. Mali Malar J. 2022;21:39.","journal-title":"Mali Malar J"},{"key":"5597_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12936-022-04115-8","volume":"21","author":"CV Plowe","year":"2022","unstructured":"Plowe CV. Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malar J. 2022;21:104.","journal-title":"Malar J"},{"key":"5597_CR43","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1016\/S2214-109X(23)00550-8","volume":"12","author":"L Braunack-Mayer","year":"2024","unstructured":"Braunack-Mayer L, Malinga J, Masserey T, Nekkab N, Sen S, Schellenberg D, et al. Design and selection of drug properties to increase the public health impact of next-generation seasonal malaria chemoprevention: a modelling study. Lancet Glob Health. 2024;12:e478\u201390.","journal-title":"Lancet Glob Health"},{"key":"5597_CR44","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa1811400","volume":"380","author":"D Chandramohan","year":"2019","unstructured":"Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, et al. Effect of adding azithromycin to seasonal malaria chemoprevention. N Engl J Med. 2019;380:2197\u2013206.","journal-title":"N Engl J Med"},{"key":"5597_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/1475-2875-9-303","volume":"9","author":"M Capan","year":"2010","unstructured":"Capan M, Mombo-Ngoma G, Makristathis A, Ramharter M. Anti-bacterial activity of intermittent preventive treatment of malaria in pregnancy: comparative in vitro study of sulphadoxine-pyrimethamine, mefloquine, and azithromycin. Malar J. 2010;9:303.","journal-title":"Malar J"},{"key":"5597_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103871","volume":"77","author":"A Waltmann","year":"2022","unstructured":"Waltmann A, McQuade ETR, Chinkhumba J, Operario DJ, Mzembe E, Itoh M, et al. The positive effect of malaria IPTp-SP on birthweight is mediated by gestational weight gain but modifiable by maternal carriage of enteric pathogens. EBioMedicine. 2022;77:103871.","journal-title":"EBioMedicine"},{"key":"5597_CR47","unstructured":"Nsubuga PWM, Thacker SB, et al. Public health surveillance: a tool for targeting and monitoring interventions. Disease control priorities in developing countries 2nd edition Washington (DC): The International Bank for Reconstruction and Development\/The World Bank; 2006 chapter 53 co-published by Oxford University Press: New York."},{"key":"5597_CR48","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/ije\/dyx201","volume":"47","author":"J Benjamin-Chung","year":"2018","unstructured":"Benjamin-Chung J, Arnold BF, Berger D, Luby SP, Miguel E, Colford JM Jr, et al. Spillover effects in epidemiology: parameters, study designs and methodological considerations. Int J Epidemiol. 2018;47:332\u201347.","journal-title":"Int J Epidemiol"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05597-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05597-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05597-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:03:29Z","timestamp":1762416209000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05597-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5597"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05597-y","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Randomized controlled trial from which the data was obtained was reviewed and approved by the Institutional Review Boards at the University of California, San Francisco and the Comit\u00e9 National d\u2019Ethique pour la Recherche (National Ethics Committee of Burkina Faso) in Ouagadougou, Burkina Faso. Written informed consent was obtained from the caregiver of each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"376"}}